Scarica l'app Stockscreener
1.80
5.76%
-0.11
Precedente Chiudi:
$1.91
Aprire:
$1.94
Volume 24 ore:
3.97M
Relative Volume:
1.88
Capitalizzazione di mercato:
$392.73M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-6.4286
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-15.49%
1M Prestazione:
-24.05%
6M Prestazione:
+20.81%
1 anno Prestazione:
+26.76%
Intervallo 1D:
$1.78
$1.94
Intervallo di 1 settimana:
$1.78
$2.14
Portata 52W:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.80 | 392.73M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 19.7% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.com - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M - MSN
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha
Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO John P. Butler Sells 144,250 Shares - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insider Sells $116,804.10 in Stock - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $106,062.60 in Stock - MarketBeat
Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of Stock - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M By Investing.com - Investing.com Canada
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 - GlobeNewswire
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and RegionAkebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition - Yahoo Finance
Akebia Therapeutics' chief accounting officer sells $63,424 in stock - MSN
Akebia Therapeutics' chief commercial officer sells $116,804 in stock - MSN
Akebia therapeutics' chief medical officer sells $106,062 in stock By Investing.com - Investing.com South Africa
Akebia therapeutics' chief medical officer sells $106,062 in stock - MSN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics CEO John Butler sells $302,925 in stock By Investing.com - Investing.com Canada
Akebia Therapeutics' chief commercial officer sells $116,804 in stock By Investing.com - Investing.com South Africa
Akebia's Latest Talent Investment: Strategic Options Grant Details Revealed - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Akebia Therapeutics CEO John Butler sells $302,925 in stock - MSN
SEC Form S-8 filed by Akebia Therapeutics Inc. - Quantisnow
Akebia Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Akebia Therapeutics (NASDAQ:AKBA) Trading 10.9% HigherTime to Buy? - MarketBeat
H.C. Wainwright maintains Akebia stock Buy rating, $7.50 target - MSN
Akebia Therapeutics (NASDAQ:AKBA) Trading Down 4.4%What's Next? - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Better Luck Next Year: US FDA CRLs May Be Rising, But Are Not The End Of The Story - News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Trading Up 10.9%Here's What Happened - MarketBeat
Lobbying Update: $240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for AKBA Issued By HC Wainwright - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akebia Therapeutics Inc Azioni (AKBA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 03 '25 |
Sale |
2.10 |
50,506 |
106,063 |
816,234 |
| Malabre Richard C | SVP, Chief Accounting Officer |
Feb 03 '25 |
Sale |
2.10 |
30,202 |
63,424 |
280,248 |
| Grund Nicholas | Chief Commercial Officer |
Feb 03 '25 |
Sale |
2.10 |
55,621 |
116,804 |
442,579 |
3.23%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):